Image by Federico Respini

Concepts in

medicine.

40+ years, 70+ breakthrough launches, 40+ partners.

Full commitment to partners, professionalism & ethics.

ABOUT ERKIM

Since 1981, we have been serving as the regional affiliate for world's most important pharmaceutical and biotechnology companies. Today, we remain one of the oldest and largest companies delivering novel treatments to patients in CEE, Mediterranean and Turkey.

OUR VALUES

Image by Joshua Earle
Image by Thiago Cerqueira
simon-rae-WMQ3D4sxNnA-unsplash.jpg

PARTNER

SUCCESS

We have redefined the role of a distributor to a true partner. We deliver a high level of quality, results and financial terms that makes Erkim an option preferred to setting up a local affiliate presence. 

ETHICAL

FOCUS

Even global companies have faced large FCPA fines due to actions of their local affiliates or distributors. We kept our commitment to ethics since 1981 and continue our unwavering commitment.

PATIENT

OUTCOMES

Through our work in key specialties in our regions, we have built long-lasting expertise, an excellent reputation and key partnerships to ensure patients can rapidly access the treatment need.

OUR REFERENCES

OUR

PARTNERS

Since 1981, we are proud to have successfully launched some of the most important treatments in our three regions. In doing so, we have built deep partnerships with 30+ global companies, aiming to provide a level of quality and commitment above and beyond what a local affiliate can.

Image by Tim Foster
Planning Travels

OUR
TERRITORIES

Er-Kim is currently actively present with wholly owned affiliates in CEE (Albania, Bosnia, Bulgaria, Croatia, Czechia, Hungary, Kosovo, Moldova, Montenegro, North Macedonia, Romania, Poland, Serbia, Slovakia and Slovenia), Mediterranean (Cyprus, Greece, Malta) and Turkey (along with Azerbaijan). Our three regions comprise 236M+ insured lives and a combined market size of EUR38B+ growing at 6%+ CAGR.

We are continuously expanding our global presence to newer regions with synergistic commercial challenges to deliver newer commercial opportunities to our partners while ensuring a larger group of patients can access the latest standards of care.